• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany
CONCLUSION: The preferred therapy after PCI in patients with AF is DAT with a NOAC and clopidogrel. In-hospital ischemic and bleeding events were rare. The recommended durations for combination therapy vary considerably.PMID:35243515 | DOI:10.1007/s00059-022-05099-6
Source: Herz - March 4, 2022 Category: Cardiology Authors: Uwe Zeymer Ralph Toelg Harm Wienbergen Hans-Peter Hobbach Alessandro Cuneo Raffi Bekeredjian Oliver Ritter Birgit Hailer Klaus Hertting Marcus Hennersdorf Werner Scholtz Peter Lanzer Harald Mudra Markus Schwefer Peter-Lothar Schwimmbeck Christoph Liebetra Source Type: research

Left atrial appendage closure : Current data and future developments
Herz. 2021 Aug 31. doi: 10.1007/s00059-021-05065-8. Online ahead of print.ABSTRACTCatheter-based left atrial appendage closure (LAAC) is currently a potential treatment option for stroke prevention in patients with atrial fibrillation and high risk for stroke/embolism as well as high bleeding risk. Due to improvements in LAAC devices, advances in implantation techniques and growing experience of the interventional teams, the safety profile of LAAC has significantly improved in recent years. These developments have led to a currently comprehensive exploration of novel indications for LAAC, such as patients with atrial fibri...
Source: Herz - August 31, 2021 Category: Cardiology Authors: Carsten Skurk Claudio Seppelt Denitsa Meteeva Markus Rheinthaler Ulf Landmesser Source Type: research

Anticoagulation in special patient populations with atrial fibrillation
Herz. 2021 Jul 5. doi: 10.1007/s00059-021-05042-1. Online ahead of print.ABSTRACTAnticoagulation in patients with atrial fibrillation (AF) should be guided by considerations of the risk of thromboembolism, stroke, and bleeding as well as the patient's preference. Well-recognized scores have been developed to help the clinician in daily risk assessment, but there are several special patient populations for whom scores are not developed or validated. Furthermore, these patients were not adequately represented in the pivotal randomized trials for non-vitamin K antagonist oral anticoagulants (NOACs). In patients with cancer, t...
Source: Herz - July 5, 2021 Category: Cardiology Authors: Laura Ueberham Gerhard Hindricks Source Type: research

New oral anticoagulants for nonvalvular atrial fibrillation with peripheral artery disease: a  meta-analysis.
CONCLUSION: The findings show that NOACs are effective and safe for preventing stroke/SE in patients with both NVAF and PAD. PMID: 32728781 [PubMed - as supplied by publisher]
Source: Herz - August 1, 2020 Category: Cardiology Tags: Herz Source Type: research

Therapeutic management of nonvalvular atrial fibrillation.
Authors: Gunawardene MA, Hartmann J, Jularic M, Eickholt C, Gessler N, Willems S Abstract Atrial fibrillation (AF) is the most frequent persistent cardiac arrhythmia and is associated with an increased mortality. Therefore, an effective differential treatment of patients is mandatory. After a risk stratification oral anticoagulation (OAC) should be initiated depending on the individual stroke risk of each patient. Alternatively, in the presence of contraindications for OAC and an increased risk for bleeding and/or stroke, the implantation of a left atrial appendage closure device can be considered. Symptomatic pati...
Source: Herz - July 9, 2020 Category: Cardiology Tags: Herz Source Type: research

Left atrial appendage closure for stroke prevention in atrial fibrillation : An update.
Authors: Zimmermann F, Landmesser U Abstract Atrial fibrillation (AF) is one of the most frequent causes of ischemic stroke. Without treatment the annual risk of ischemic stroke is on average approximately 5-6%/year in patients with atrial fibrillation, depending on the overall cardiovascular risk profile. Oral anticoagulation with new oral anticoagulants (NOAC) or vitamin K antagonists (VKA) is recommended for patients with AF and an elevated risk for stroke (CHA2DS2-VASc score ≥1); however, severe bleeding complications are potential reasons for discontinuation of this treatment. Overall, up to 30 % of the pa...
Source: Herz - May 18, 2020 Category: Cardiology Tags: Herz Source Type: research

Pages: 1  2